CACLP - The largest IVD Expo & Conference

CST and Leica Biosystems partner to enable companion diagnostics for personalized medicine

Industry news | 27 September, 2023 | CACLP

Original from: news-medical

 

Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, is partnered with Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, to support the development of companion diagnostics (CDx) assays using the extensive portfolio of best-in-class antibodies from CST validated for immunohistochemistry (IHC). Leica is a global market leader in enabling the translation of pre-clinical research into CDx tests, helping pharma partners develop and commercialize cutting-edge diagnostic solutions to identify patients likely to benefit from emerging therapeutics.

 

Clinical trial recruitment and assessment of patient biomarker status are dependent on the use of effective and reliable CDx assays as a critical component of guiding treatment decisions for personalized medicine. Since 2020, this agreement has facilitated the use of trusted CST® antibodies to unique biomarkers by the Leica Biosystems CDx team to enable leading biotechnology and pharmaceutical companies to leverage these fit-for-purpose tools to support the drug development workflow.

“Ensuring the availability of trusted, highly validated antibody products from initial discovery through translation and CDx development streamlines the pharmaceutical development process and de-risks product commercialization,” said Roberto Polakiewicz, Chief Scientific Officer at CST. “Strategic partnerships like this help drive precision medicine forward by enabling more rapid and efficient development of new therapies to devastating diseases. We're excited to continue working with Leica's leading CDx team to support the advancement of biotherapeutics from discovery through to the clinic.”

 

"Since the establishment of our Companion Diagnostics Team in 2012, our expertise in immunohistochemistry, in situ hybridization, and automation has enabled assay development for a diverse range of biomarker targets across a variety of cancer types for our Biopharma partners. We are excited to collaborate with CST to develop transformative companion diagnostics for the advancement of personalized medicine for cancer patients.” said Rob Monroe, Chief Medical Officer, Leica Biosystems.

 

​CST was named Antibody Supplier of the Decade and the 2022 Supplier Succeeding in Cancer Research by CiteAb due to the company's commitment to rigorous validation standards, strong scientific foundation, and ever-expanding portfolio of antibody reagentsto unique biomarkers. Across the industry, CST antibodies are trusted for their sensitivity, specificity, and reproducible performance in the assays in which they are validated.​

 

Source: CST and Leica Biosystems partner to enable companion diagnostics for personalized medicine

 

Filed under:
Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference